Physicians' Academy for Cardiovascular Education

Reversal agent for FXa inhibitors is effective and safe in interim analysis of ANNEXA-4 trial

3' education - Mar. 11, 2018 - Prof. Stuart Connolly, Hamilton, ON, Canada

ACC 2018 Prof. Connolly summarizes the results of the interim analysis of the ANNEXA-4 trial: andexanet was effective in the reversal of the effect of FXa inhibitors and reversed FXa-associated bleedings in patients with acute major bleedings.

Educational information

This 3-minute education provides a summary of just presented scientific data, recorded during the ACC 2018. The objective is to provide a brief commentary and potential implications of these findings.


Dr. Stuart Connolly is a professor of Medicine at McMaster University and a cardiac electrophysiologist at Hamilton Health Sciences.


This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of PACE-cme.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: